These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37492892)

  • 1. Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-β Status in Parkinson's disease-Related Cognitive Decline.
    Labrador-Espinosa MA; Silva-Rodríguez J; Reina-Castillo MI; Mir P; Grothe MJ
    Mov Disord; 2023 Oct; 38(10):1871-1880. PubMed ID: 37492892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
    Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
    Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study.
    Grothe MJ; Labrador-Espinosa MA; Jesús S; Macías-García D; Adarmes-Gómez A; Carrillo F; Camacho EI; Franco-Rosado P; Lora FR; Martín-Rodríguez JF; Barberá MA; Pastor P; Arroyo SE; Vila BS; Foraster AC; Martínez JR; Padilla FC; Morlans MP; Aramburu IG; Ceberio JI; Vara JH; de Fábregues-Boixar O; de Deus Fonticoba T; Pascual-Sedano B; ; Kulisevsky J; Martínez-Martín P; Santos-García D; Mir P
    Parkinsonism Relat Disord; 2021 Jul; 88():68-75. PubMed ID: 34144230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease.
    Schumacher J; Kanel P; Dyrba M; Storch A; Bohnen NI; Teipel S; Grothe MJ
    Brain; 2023 Dec; 146(12):4964-4973. PubMed ID: 37403733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Filippi M; Canu E; Donzuso G; Stojkovic T; Basaia S; Stankovic I; Tomic A; Markovic V; Petrovic I; Stefanova E; Kostic VS; Agosta F
    Mov Disord; 2020 Nov; 35(11):1987-1998. PubMed ID: 32886420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Gang M; Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Hasegawa T; Aoki M; Takeda A; Mori E; Suzuki K
    Mov Disord; 2020 May; 35(5):825-832. PubMed ID: 31971293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
    Pereira JB; Hall S; Jalakas M; Grothe MJ; Strandberg O; Stomrud E; Westman E; van Westen D; Hansson O
    Neurobiol Dis; 2020 Jun; 139():104831. PubMed ID: 32145376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.
    Mak E; Su L; Williams GB; Firbank MJ; Lawson RA; Yarnall AJ; Duncan GW; Owen AM; Khoo TK; Brooks DJ; Rowe JB; Barker RA; Burn DJ; O'Brien JT
    Brain; 2015 Oct; 138(Pt 10):2974-86. PubMed ID: 26173861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Basal Forebrain Atrophy With Cognitive Decline in Early Alzheimer Disease.
    Xia Y; Dore V; Fripp J; Bourgeat P; Laws SM; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe C; Masters CL; Coulson EJ; Maruff P
    Neurology; 2024 Jul; 103(2):e209626. PubMed ID: 38885444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cortical atrophy is associated with cognitive impairment in Parkinson's disease: a combined analysis of cortical thickness and functional connectivity.
    Zhu Y; Yang B; Zhou C; Gao C; Hu Y; Yin WF; Yin K; Zhu Y; Jiang G; Ren H; Pang A; Yang X
    Brain Imaging Behav; 2022 Dec; 16(6):2586-2600. PubMed ID: 36044168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson's disease.
    Gargouri F; Gallea C; Mongin M; Pyatigorskaya N; Valabregue R; Ewenczyk C; Sarazin M; Yahia-Cherif L; Vidailhet M; Lehéricy S
    Mov Disord; 2019 Apr; 34(4):516-525. PubMed ID: 30536444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Wilson J; Yarnall AJ; Craig CE; Galna B; Lord S; Morris R; Lawson RA; Alcock L; Duncan GW; Khoo TK; O'Brien JT; Burn DJ; Taylor JP; Ray NJ; Rochester L
    Mov Disord; 2021 Mar; 36(3):611-621. PubMed ID: 33382126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson disease.
    Barrett MJ; Murphy JM; Zhang J; Blair JC; Flanigan JL; Nawaz H; Dalrymple WA; Sperling SA; Patrie J; Druzgal TJ
    Parkinsonism Relat Disord; 2021 Sep; 90():27-32. PubMed ID: 34348192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower volume, more impairment: reduced cholinergic basal forebrain grey matter density is associated with impaired cognition in Parkinson disease.
    Barrett MJ; Sperling SA; Blair JC; Freeman CS; Flanigan JL; Smolkin ME; Manning CA; Druzgal TJ
    J Neurol Neurosurg Psychiatry; 2019 Nov; 90(11):1251-1256. PubMed ID: 31175168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.
    Dadar M; Zeighami Y; Yau Y; Fereshtehnejad SM; Maranzano J; Postuma RB; Dagher A; Collins DL
    Neuroimage Clin; 2018; 20():892-900. PubMed ID: 30292088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally.
    Hanganu A; Bedetti C; Degroot C; Mejia-Constain B; Lafontaine AL; Soland V; Chouinard S; Bruneau MA; Mellah S; Belleville S; Monchi O
    Brain; 2014 Apr; 137(Pt 4):1120-9. PubMed ID: 24613932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphometric magnetic resonance imaging cortico-subcortical features in Parkinson's disease with mild cognitive impairment.
    Cicero CE; Donzuso G; Luca A; Davì M; Baschi R; Mostile G; Giuliano L; Palmucci S; Salerno A; Monastero R; Nicoletti A; Zappia M
    Eur J Neurol; 2022 Nov; 29(11):3197-3204. PubMed ID: 35790057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of Parkinson's disease patients' subtypes based on cortical thinning: 4-year follow-up.
    Uribe C; Segura B; Baggio HC; Abos A; Garcia-Diaz AI; Campabadal A; Marti MJ; Valldeoriola F; Compta Y; Bargallo N; Junque C
    Parkinsonism Relat Disord; 2019 Jul; 64():286-292. PubMed ID: 31103485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial cognitive decline is associated with cortical thinning in early Parkinson disease.
    Pereira JB; Svenningsson P; Weintraub D; Brønnick K; Lebedev A; Westman E; Aarsland D
    Neurology; 2014 Jun; 82(22):2017-25. PubMed ID: 24808018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.